academic article

• The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome..  Breast cancer research and treatment.  171:273-282. 2018
• Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen..  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.  23:785-790. 2012
• Epidermal growth factor receptor as a biomarker for cervical cancer..  Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.  22:2166-2178. 2011
• Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms..  International journal of surgical pathology.  19:588-596. 2011
• Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma..  American journal of obstetrics and gynecology.  203:242.e1-242.e5. 2010
• Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer..  Clinical cancer research : an official journal of the American Association for Cancer Research.  16:2999-3010. 2010
• GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer..  Breast cancer research and treatment.  123:51-58. 2010
• Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors..  Gynecologic oncology.  114:480-485. 2009
• GPR30 predicts poor survival for ovarian cancer..  Gynecologic oncology.  114:465-471. 2009